Avalo Therapeutics, Inc.
AVTX
$18.20
$0.201.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -43.08% | 55.20% | -47.48% | -57.92% | 62.79% |
| Total Depreciation and Amortization | 6.25% | -72.88% | -55.97% | -0.74% | 98.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 517.97% | -104.68% | 172.74% | 138.43% | -88.68% |
| Change in Net Operating Assets | -713.07% | 115.36% | -131.71% | 201.92% | 295.59% |
| Cash from Operations | -24.18% | 12.95% | -43.68% | -20.44% | 37.14% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 962.27% | 118.11% | 81.29% | -- | -- |
| Cash from Investing | 962.27% | 118.11% | 81.29% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 89.56% | -92.00% | 35,825.00% | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | 99.80% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 103.64% | -95.22% | 3,163.75% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 182.57% | 26.87% | 81.56% | -774.69% | -117.96% |